**2** 001/007

## RECEIVED **CENTRAL FAX CENTER**

FEB 1 0 2006

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons	.a.s. a <u>s are required to respond to a c</u>	Patent and i Dilection of inf	raciemank Child omnation unles	e; U.S. DEPARTMENT OF COMMERCE s it displays a valid OMB control number.	
	Application Number		10/633,843		
TRANSMITTAL	Filing Date	8/4/2003	8/4/2003		
FORM	First Named Inventor	C. Frank 8	iennett		
	Art Unit	1635	,		
(to be used for all correspondence after initial filling)	Examiner Name	Terra C. G	lbbs		
7	Attomey Docket Number	RTS-0242	US.C1		
Total Number of Pages in This Submission /					
ENCLOSURES (Check all that apply)					
Fee Transmittal Form	Drawing(s)			er Allowance Communication to TC	
Fee Attached	icensing-related Papers			oppeals and Interferences	
L Amenomenukepiy	Petition Petition to Convert to a			peal Communication to TC peal Notice, Brief, Reply Brief)	
After Final	rovisional Application ower of Attorney, Revocation			prietary information	
	Change of Correspondence		; <u> </u>	tus Letter er Enclosure(s) (please Identify	
Extension of Time Request	ferminal Disclaimer			OM):	
Express Abandonment Request	Request for Refund		}		
Information Disclosure Statement	CD, Number of CD(s)		İ		
Landscape Table on CD					
Certified Copy of Priority Remarks Document(s)					
Reply to Missing Parts/					
Incomplete Application Reply to Missing Parts					
under 37 CFR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name Isis Pharmaceuticals, Inc.					
Signature PULLICE					
Printed name Colleen J. McKlernan, Ph.D.					
Date Feb 10, 2006		Reg. No.	46,570		
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:					
Signature Laureur					
Typed or printed name Laura Earnes	· <u></u>		Dat	2/10/04	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a bornelit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA. 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

02/10/2006 14:18 FAX 7606033820

Serial No.: 10/633,843

RTS-0242US.C1

# RECEIVED CENTRAL FAX CENTER

FEB 1 0 2006

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

RTS-0242US.C1

Inventors:

Bennett and Dobie

Serial No.:

10/633,843

Filing Date:

August 4, 2003

Examiner:

Terra C. Gibbs

Group Art Unit:

1635

Title:

Antisense Modulation of

Superoxide Dismutase 1, Soluble

Expression

#### Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at facsimile number 571-293-8300 on the date shown below.

On February 10, 2006

Laura Eamas

Mail Stop- No Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Reply and Request for Reconsideration under 37 CFR

1.111(a)

Dear Examiner Gibbs:

This reply is in response to the outstanding office action in this case with a mailing date of November 15, 2005 setting a three month period of time for response.

The Amendments to the Claims are reflected in the listing of claims which begins on page 2.

Remarks begin on page 4.